Abstract 146P
Background
Esophageal cancer is an aggressive cancer with a poor prognosis. Prognostic factors are mainly based on cancer staging. HSPs are molecular chaperones that help protect against stress, often overexpressed in esophageal cancer. However, the prognostic significance and regulatory factors, such as HSF1 and CHIP, are poorly understood. To address the gap, a meta-analysis was conducted to investigate the relationship between HSP expression, prognosis-related factors, and clinicopathological features of esophageal cancer.
Methods
A systematic review was conducted by two reviewers on patients with esophageal cancer until Feb 15 2023. The study compared patients with positive HSP proteins to HSP-negative patients, analyzing grade of differentiation, lymph node metastasis, tumor depth, distant metastasis, and overall survival. HSP were stratified by HSP family, and summary risk difference (RD) were calculated using a random-effect model. Statistical heterogeneity was calculated using I2 statistic, and the risk and bias assessment, using the ROBINS-I tool. This study was conducted in accordance with PRISMA statement recommendations.
Results
Final selection comprised 27 studies, with a pooled sample size of 3465 patients. The mean age was 60.7 years old (46-69), with a male predominance. HSP40 and 60 were associated with a higher 3-year overall survival (HSP40 RD: 0.22; 95% CI: 0.09 to 0.35; HSP60 RD: 0.33; 95% CI: 0.17 to 0.50), while HSF1 was associated with a poor 3-year overall survival (RD: -0.22; 95% CI: -0.32 to -0.12). HSF1 was associated with a higher probability of lymph nodal metastasis (RD: -0.16; 95% CI: -0.29 to -0.04). HSP40 was associated with lower probability for lymph nodal dissemination (RD: 0.18; 95% CI: 0.03 to 0.33). HSP were not found to be related to lymph nodal metastasis, tumor depth or distant metastasis. Besides, HSPs were not related to grade of cellular differentiation.
Conclusions
Our systematic review and meta-analysis showed that the expressions of certain families of HSP, such as HSP40 and 60, HSF1 are associated with long-term survival and lymph nodal dissemination in patients with esophageal cancer. These findings support the role of HSP in susceptibility, progression and prognosis in esophageal cancer.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Universidade de São Paulo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
145P - Identification of next generation sequencing (NGS)-based genomic signature predicting resistance to immunotherapy (IO) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): A single-center cohort study
Presenter: Antonio Vitale
Session: Cocktail & Poster Display session
Resources:
Abstract
148P - Identification of potential predictive biomarkers for ovarian cancer chemotherapy response
Presenter: Alsina Nurgalieva
Session: Cocktail & Poster Display session
Resources:
Abstract
149P - Rare RAS mutations are associated with recurrence patterns and recurrence-free survival in colon cancer: First results from Morocco
Presenter: Fatima Agy
Session: Cocktail & Poster Display session
Resources:
Abstract
151P - Development of a predictive model for response to neoadjuvant chemoradiation therapy of rectal cancer using the immunologic profile
Presenter: Eun Shin
Session: Cocktail & Poster Display session
Resources:
Abstract
152P - Biomarkers of neoadjuvant chemoradiotherapy response in locally advanced rectal cancer
Presenter: Cibele Masotti
Session: Cocktail & Poster Display session
Resources:
Abstract
153P - BRAF variants and therapy outcomes in melanoma
Presenter: Eftychia Chatziioannou
Session: Cocktail & Poster Display session
Resources:
Abstract
154P - The impact of proton pump inhibitors in the prognosis of patients with non-metastatic nasopharyngeal carcinoma
Presenter: João Barbosa Martins
Session: Cocktail & Poster Display session
Resources:
Abstract
155P - Use of machine learning for the identification of molecular biomarkers to predict response to neoadjuvant chemotherapy in locally advanced breast cancer patients
Presenter: María Del Río Pisula
Session: Cocktail & Poster Display session
Resources:
Abstract
156P - Molecularly driven therapy recommended by a molecular tumor board: Accessible option or privilege for a minority of patients? A single-center experience from the Czech Republic
Presenter: Michal Eid
Session: Cocktail & Poster Display session
Resources:
Abstract
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract